USP9X and acute lymphoblastic leukemia: It is reported that pharmacological or genetic inhibition of USP9X, as well as treatment with low-dose ruxolitinib, may promote the survival of CRLF2-positive B-ALL with down syndrome (DS-ALL) cells, potentially by restricting JAK signaling [117].